

Vitrification:				
"Robots" versus Human				
Comparing automated vitrification outcomes				
The 5th World congress of the INTERNATIONAL SOCIETY FOR FERTILITY PRESERVATION Vienna, Austria November 16-18, 2017				
Zsolt Peter NAGY, M.D., Ph.D. HCLD				
Scientific Director				
Reproductive Biology Associates Atlanta, USA				


Disclosure	
Direct stockholder:	My Egg Bank/Prelude
Scientific Advisory Board:	Cooper Surgical/Origio
Paid Consultant:	EMD-Serono
Speakers bureau:	MERCK MSD

	Oocyte Freezing History						
Slow freezing of domestic animal embryos	Slow Slow freezing of freezing of human embryos ocytes	Ultrarapid Vitrification with EM orids OPS	Vitrification Egg	of Donor Banks RBA/MEB ASRM 2013 Egg cryo Not			
freezing of mouse embryos	of mouse of b embryos blas	Ultrarapid Vitrification fication ovine stocysts	Egg Banking Fertility Preservation Egg Cryo	experimental Start of routine FP Medical, Social, - AFP			
	1983 1985 1989 1 ngham et al., Wilmu		99 2002 2004 2006	2009 2013 2015			




















Forest plots of clinical pregnancy rate per warmed oocyte for studies comparing fresh with vitrified oocytes. Donor and non-donor oocyte studies.


3.2.1 Donor oocyte studies Cobo et al. 2010 148 3286 144 3185 36.4% 1.00 [0.79, 1.26] Garcia et al., 2011 41 283 101 696 13.0% 1.00 [0.67, 1.48] Trokoudes et al. 2011 20 210 20 247 4.3% 1.19 [0.62, 2.29] Subtotal (95% CI) 3779 4128 53.7% 1.01 [0.84, 1.23] Total events 209 265 Heterogeneity: Chi ² = 0.27, df = 2 ($P = 0.87$); $I^2 = 0\%$ Test for overall effect: Z = 0.13 ($P = 0.90$) 3.2.2 Non-donor oocyte studies Almodin et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Parmegiani et al. 2011 11 168 4 120 1.1% 2.03 [0.63, 6.54] Rienzi et al. 2010 15 124 54 120 12.6% 0.17 [0.09, 0.32] Ubaldi et al. 2010 35 487 77 511 18.2% 0.44 [0.29, 0.66] Subtotal (95% CI) 1361 2283 46.3% 0.72 [0.57, 0.90] Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 ($P < 0.00001$); $I^2 = 91\%$ Test for overall effect: Z = 2.86 ($P = 0.004$) Total (95% CI) 5140 6511 100.0% 0.87 [0.76, 1.01]		Vitrifica	ation	Fres	h		Odds Ratio	Odds Ratio
Cobo et al. 2010 148 3286 144 3185 36.4% 1.00 [0.79, 1.26] Garcia et al., 2011 41 283 101 696 13.0% 1.00 [0.67, 1.48] Trokoudes et al. 2011 20 247 4.3% 1.19 [0.62, 2.29] Subtotal (95% CI) 3779 4128 53.7% 1.01 [0.84, 1.23] Total events 209 265 Heterogeneity: Chi ² = 0.27, df = 2 (P = 0.87); l ² = 0% Test for overall effect: Z = 0.13 (P = 0.90) 3.2.2 Non-donor oocyte studies Almodin et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2017 39 330 71 726 10.2% 1.24 [0.82, 1.87] Parmegiani et al. 2010 15 124 54 120 0.17 [0.09, 0.32]	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Garcia et al., 2011 41 283 101 696 13.0% 1.00 [0.67, 1.48] Trokoudes et al. 2011 20 210 20 247 4.3% 1.19 [0.62, 2.29] Subtotal (95% CI) 3779 4128 53.7% 1.01 [0.84, 1.23] Total events 209 265 Heterogeneity: Chi ² = 0.27, df = 2 (P = 0.87); l ² = 0% Test for overall effect: Z = 0.13 (P = 0.90) 3.2.2 Non-donor oocyte studies Almodin et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2010 21 252 41 906 4.3% 1.92 [0.82, 1.87] Parmegiani et al. 2011 11 168 4 120 1.24 [0.82, 1.87] Parmegiani et al. 2010 15 124 54 120 1.96 (0.17 [0.09, 0.32] Ubadia et al. 2010 15 124 54 0.72 [0.57, 0.90] 1036 Subtotal (95% CI) 1361 2383 46.3% 0.72 [0.57, 0.90] 104 Total events 121 247 247 4.63% 0.72 [0	3.2.1 Donor oocyte stu	dies						
Trokoudes et al. 2011 20 210 20 247 4.3% 1.19 [0.62, 2.29] Subtotal (95% CI) 3779 4128 53.7% 1.01 [0.84, 1.23] Total events 209 265 Heterogeneity: Chi ² = 0.27, df = 2 ($P = 0.87$); $i^2 = 0\%$ Test for overall effect: Z = 0.13 ($P = 0.90$) 3.2.2 Non-donor occvte studies Almodin et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2010 39 330 71 726 10.2% 1.24 [0.82, 1.87] Parmegiani et al. 2011 11 168 4 120 1.1% 2.03 [0.63, 6.54] Rienzi et al. 2010 15 124 54 120 12.6% 0.17 [0.09, 0.32] Ubaldi et al. 2010 35 487 77 511 18.2% 0.44 [0.29, 0.66] Subtotal (95% CI) 1361 2383 46.3% 0.72 [0.57, 0.90] Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 ($P < 0.00001$); $i^2 = 91\%$ Test for overall effect: Z = 2.86 ($P = 0.004$) Total (95% CI) 5140 6511 100.0% 0.87 [0.76, 1.01]	Cobo et al. 2010	148	3286	144	3185	36.4%	1.00 [0.79, 1.26]	
Subtotal (95% Cl) 3779 4128 53.7% 1.01 [0.84 , 1.23] Total events 209 265 Heterogeneity: Chi ² = 0.27, df = 2 (P = 0.87); l ² = 0% Test for overall effect: Z = 0.13 (P = 0.90) 3.2.2 Non-donor oocvte studies Almodin et al. 2010 21 252 41 906 4.3% 1.92 [1.11 , 3.31] Antinori et al. 2010 21 252 41 906 4.3% 1.92 [1.11 , 3.31] Antinori et al. 2010 21 252 41 906 4.3% 1.92 [1.11 , 3.31] Antinori et al. 2010 15 124 54 120 1.26% 0.17 [0.09 , 0.32] Ubaldi et al. 2010 35 487 77 511 18.2% 0.44 [0.29 , 0.66] Subtotal (95% Cl) 1361 2383 46.3% 0.72 [0.57 , 0.90] 100 Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); l ² = 91% 190.0% 0.87 [0.76 , 1.01] Total (95% Cl) 5140 6511 100.0% 0.87 [0.76 , 1.01]	Garcia et al., 2011	41	283	101	696	13.0%	1.00 [0.67, 1.48]	+
Heterogeneity: $Chi^2 = 0.27$, $df = 2$ ($P = 0.87$); $l^2 = 0\%$ Test for overall effect: $Z = 0.13$ ($P = 0.90$) 3.2.2 Non-donor oocyte studies Almodin et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2017 39 330 71 726 10.2% 1.24 [0.82, 1.87] Parmegiani et al. 2011 11 168 4 120 11.% 2.03 [0.63, 6.54] Rienzi et al. 2010 15 124 54 120 12.6% 0.17 [0.09, 0.32] Ubaldi et al. 2010 35 487 77 511 18.2% 0.44 [0.29, 0.66] Subtotal (95% Cl) 1361 2383 46.3% 0.72 [0.57, 0.90] Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 ($P < 0.00001$); $l^2 = 91\%$ Test for overall effect: $Z = 2.86$ ($P = 0.004$) Total (95% Cl) 5140 6511 100.0% 0.87 [0.76, 1.01]		20		20				$\overline{\mathbf{\Phi}}$
Almodin et al. 2010 21 252 41 906 4.3% 1.92 [1.11, 3.31] Antinori et al. 2007 39 330 71 726 10.2% 1.24 [0.82, 1.87] Parmegiani et al. 2011 11 168 4 120 1.1% 2.03 [0.63, 6.54] Rienzi et al. 2010 15 124 54 120 12.6% 0.17 [0.09, 0.32] Ubadi et al. 2010 35 487 77 511 18.2% 0.44 [0.29, 0.66] Subtotal (95% CI) 1361 2483 46.3% 0.72 [0.57, 0.90] Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); l ² = 91% Test for overall effect: Z = 2.86 (P = 0.004) Total (95% CI) 5140 6511 100.0% 0.87 [0.76, 1.01]	Total events	209		265				$\mathbf{\Psi}$
Antinori et al. 2007 39 330 71 726 10.2% 1.24 $(0.82, 1.87)$ Parmegiani et al. 2011 11 168 4 120 1.1% 2.03 $[0.63, 6.54]$ Rienzi et al. 2010 15 124 54 120 1.1% 2.03 $[0.63, 6.54]$ Bienzi et al. 2010 35 487 77 511 18.2% 0.44 $[0.29, 0.66]$ Subtotal (95% CI) 1361 2383 46.3% 0.72 $[0.57, 0.90]$ Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); l ² = 91% Test for overall effect: Z = 2.86 (P = 0.004) Total (95% CI) 5140 6511 100.0% 0.87 $[0.76, 1.01]$				¥3				
Parmegiani et al. 2011 11 168 4 120 1.1% 2.03 [0.63, 6.54] Rienzi et al. 2010 15 124 54 120 12.6% 0.17 [0.09, 0.32] Ubaldi et al. 2010 35 487 77 511 18.2% 0.44 [0.29, 0.66] Subtotal (95% CI) 1361 2383 46.3% 0.72 [0.57, 0.90] Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); l ² = 91% Test for overall effect: Z = 2.86 (P = 0.004) Total (95% CI) 5140 6511 100.0% 0.87 [0.76, 1.01]	Almodin et al. 2010	21	252	41	906	4.3%	1.92 [1.11, 3.31]	
Rienzi et al. 2010 15 124 54 120 12.6% 0.17 [0.09, 0.32] Ubaldi et al. 2010 35 487 77 511 18.2% 0.44 [0.29, 0.66] Subtotal (95% Cl) 1361 2383 46.3% 0.72 [0.57, 0.90] Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); l ² = 91% Test for overall effect: Z = 2.86 (P = 0.004) Total (95% Cl) 5140 6511 100.0% 0.87 [0.76, 1.01]	Antinori et al. 2007	39	330	71	726	10.2%	1.24 [0.82, 1.87]	
Ubaldi et al. 2010 35 487 77 511 18.2% 0.44 $(0.29, 0.66]$ Subtotal (95% CI) 1361 2383 46.3% 0.72 $[0.57, 0.90]$ Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); i ² = 91% Test for overall effect: Z = 2.86 (P = 0.004) Total (95% CI) 5140 6511 100.0% 0.87 $[0.76, 1.01]$	Parmegiani et al. 2011	11	168	4	120	1.1%	2.03 [0.63, 6.54]	
Subtotal (95% Cl) 1361 2383 46.3% 0.72 [0.57, 0.90] Total events 121 247 Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); l ² = 91% 12 Test for overall effect: Z = 2.86 (P = 0.004) 0.87 [0.76, 1.01]	Rienzi et al. 2010	15	124	54	120	12.6%	0.17 [0.09, 0.32]	
Heterogeneity: Chi ² = 46.75, df = 4 (P < 0.00001); i ² = 91% Test for overall effect: Z = 2.86 (P = 0.004) Total (95% CI) 5140 6511 100.0% 0.87 [0.76, 1.01] ♦		35		77				$\overline{\mathbf{O}}$
Test for overall effect: Z = 2.86 (P = 0.004) Total (95% CI) 5140 6511 100.0% 0.87 [0.76, 1.01]	Total events	121		247				
Total (95% CI) 5140 6511 100.0% 0.87 [0.76, 1.01]); $1^2 = 9$	91%		
	Test for overall effect: Z	: = 2.86 (P	= 0.00	4)				
Total events 330 512	Total (95% CI)		5140		6511	100.0%	0.87 [0.76, 1.01]	•
	Total events	330		512				
Test for overall effect: $Z = 1.79$ (P = 0.07)	Heterogeneity: $Chi^2 = 5$				$(1^{-1} = 0)$	50%		0.01 0.1 1 10













RBA experience on oocyte freezing				
Clinical evaluation of the efficiency of an oocyte do DP, Elsner CW, Mitchell-Leef D, Toledo AA, Kort H		king. Nagy ZP, Chang CC, Shapiro DB, Bernal		
	Cryo Egg	Fresh Egg		
Recipients	20	10		
M2 Egg/Pat	7.7	31.7		
Es for ET (x)	47 (2.4)	19 (2.1)		
Es for Cryo (x)	31 (1.5)	141 (16)		
PR (IR)	75% (54%)	56% (47%)		
Cumulative PR	85%	78%		
Recipients Pregnant	17	7 Nagy et al, 2009		





MEB experience on donor egg banking				
Donation cycles	1,035			
M2 vitrified	23,060 (22.3/Don.)			
Recipient cycles	3,424			
M2 Warmed	21,462 (6.3/Rec.)			
Survival	88%			
Fertilization	78%			
Pregnancy (clinical)	52%			




Results		egg vitrifi	Jalion
Results	eSET	eDET	Non-eDET
Number of Recipients	98	109	233
Implanted	51	112	171
Embryos	(52%)	(51%)	(37.5%)
Clinical	51	79	121
Pregnancies	(52%)	(72.4%)*	(51.9%)
Multiple	0	40	37
pregnancies	(0%)*	(50.6%)	(30%)




Vitrified Embryos From Vitrified Eggs ("Double Vitrification")			
100 patients (Cryo Egg Bank)	<u>Cryo Embryo</u>		
Number of warmed embryos	190		
Survived	189 (99%)		
No of Es for ET (x)	176 (1.8)*		
Pregnancies (Clinical)	l) 53 (53%)		
Implantation / FCA	A 68 (39%)		
Miscarriages	12		
Live births (limited data)	33		
Girls	15		
Boys	18		


Transporting vitrified oocytes (embryos)?				
IN-HOUSE DONORS VS	OUTSIDE (SHIPPED EGGS	S) LOCATION DONORS		
	IN HOUSE DONORS (vit. Eggs – No-Transport)	OUTSIDE DONORS (Transported vit. Eggs)		
#CYCLES	1175	63		
#DONOR CYCLES	444	52		
DONOR AVG. AGE SD	25.8 2.8	25.8 3.1		
PATIENT AVG. AGE ±SD	40.9 ±4.71	40.6 ±3.9		
AVG. # MII WARMED SD*	6.2 ± 1.85	7.0 ± 1.0		
SURVIVAL RATE	91.0%	89.4%		
FERTILIZATION RATE	85.0%	83.8%		
BLASTOCYSTS RATE	66.2%	63.0%		
AVG. # EMBRYOS TRANSFERRED*	1.5 ± 0.54	1.2 ± 0.4		
IMPLANTATION RATE	51.3%	48.0%		
CLINICAL PREGNANCY RATE	61.6%	57.1%		
*P <0.5				




Outcomes from fresh and warming cycles in patients who					
choose to electively cryopreserve part of their oocytes					
RBA, 2013	FRESH CYCLE	WARMING CYCLE			
# PATIENTS / CYCLES	37/42	34/34			
AVG. AGE ± S.D.	32.6 ± 3.70	33.6 ± 3.51			
AVG. # OOCYTES RETRIEVED	31.6	-			
AVG. # MII OOCYTES ±S.D.	22.8 ± 10.9	-			
AVG. # MII VITRIFIED ± S.D.	13.1 ± 8.9	-			
AVG. # MII WARMED ± S.D.		9.6 ± 7.48			
SURVIVAL RATE ±S.D. (n)	-	82.9%			
AVG. No. OOCYTES ICSI ±S.D.	9.2 ± 5.31	8.0 ± 6.72			
FERTILIZATION RATE ±S.D. (n)	71.5%	77.9%			
BLASTOCYST RATE ±S.D. (n)	43.0%	49.8%			
AVG. # EMBRYOS TRANSFERRED	1.4	1.7			
IMPLANTATION RATE (n)	16%	25%			
CLINICAL PREGNANCY RATE (n)	33%	41%			



RBA experience:	IVF patients	30–39 yea	ars
Prospective controlled study to evaluate laboratory and dinical Chang CC, Elliott TA, Wright G, Shapiro DB, Toledo AA, Nagy.		in vitro fertilization patients aged 30	to 39 years.
	Young 30–36 y (n=11)	Advanced 37–39 y (n=11)	Ρ
Patient age (mean±SD)	32.9 ± 1.9	37.9 ±0.8	<.01
Survival rate (%)	82.5	76.4	NS
Fertilization rate (%)	70.1	62.9	NS
Day 3 good Embryo (%)	55.6	40.4	<.05
Embryos transferred	24 (2.18)	29 (2.64)	NS
Clinical pregnancies (%)	7/11 (63.6)	3/11 (27.3)	NS
Implantations (%)	10/24 (41.7)	6/29 (20.7)	NS
Take home babies (%)	6/11 (54.5)	2/11 (18.2)	NS
No. of live births	8	3	-
Oocyte to Live birth (%)	8/97 (8.2)	3/89 (3.3)	NS
Chang et al FS, 2013	NEED 12 EGGS	NEED 30 EGGS	



Live Birth Data from Egg Cryo from RBA Including deliveries until the end of 2011				
	Fresh Donor	Cryo Donor		
No. of patients / Deliveries	58	257		
Recipient Age	39.9 <u>+</u> 5.6	41.3 <u>+</u> 4.5		
Live births (infants born)	Live births (infants born) 91 338			
Term delivery 37 weeks28188				
Congenital anomaly* 3 /58 5 / 257				
All deliveries	2659.4 <u>+</u> 690.9	2938.3 <u>+</u> 770.0		
Singleton/twin/triplet deliveries	26/31/1	178/77/2		
Term deliveries	3361.2 <u>+</u> 677.2	3518.8 <u>+</u> 585.2		
Down sy. 2xHemangioma Congenital anomalies: heart murmur, 1 baby died at 2 months with multiple complications, cleft lip/palate, club foot, spina bifida (TAB)				





Automated vitrification - RESULTS				
Embryo Randomization				
Patients must have at least one embryo suitable for TE biopsy and freezing on day 5 or day 6				
Embryo assignment was based on Patient Number and blastocyst grading criteria				
Embryos suitable for biopsy and freeze	ODD patient number #	EVEN patient number #		
1 st embryo	Gavi	Cryotop		
2 nd embryo	Cryotop	Gavi		
3 rd and/or additional embryos not included in this study				

Automated vitrification				
Clinical Results: Recovery and Survival Rates				
Values	Gavi	Cryotop		
Average of Age	36.21	36.24		
# of Warmed	209	238		
Recovered	207 (99.0%)	238 (100%)		
Survived \geq 75%	205 (99.0%)	235 (98.7%)		
Embryo Transferred	205 (98.1%)	235 (98.7%)		

Automated vitrification					
Clinical Results: Outcomes to Fetal Heart					
Values	Gavi	Cryotop			
# of Embryo Transferred	205	235			
Biochemical Pregnancy (+βHCG)	137 (66.8%)	154 (65.5%)			
Implantation Rate (FH rate)	119 (58.0%)	137 (58.3%)			

